Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Lipsky, Peter E ^a   Calabrese, Leonard H ^b   Kavanaugh, Arthur ^c   Sundy, John S ^d   Wright, David ^e   Wolfson, Marsha ^f   Becker, Michael A ^g  

^a Lerner College of Medicine Cleveland Clinic Foundation ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Savient Pharmaceuticals Inc   (United States)

^f Formerly of Savient Pharmaceuticals Inc   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PEGLOTICASE; URIC ACID; ANTIBODIES; POLYETHYLENE GLYCOLS; URATE OXIDASE;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GOUT; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; BLOOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOLOGY;

ANTIBODIES; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GOUT; HUMANS; POLYETHYLENE GLYCOLS; URATE OXIDASE;

EID: 84897946411     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4497     Document Type: Article

References (22)

1. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008, 75:S5-S8.
2. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012, 9:1319-1323. 10.1517/17425247.2012.720969, 22931049.
3. Hudson PB, London M. Purification and properties of solubilized uricase. Biochim Biophys Acta 1956, 21:290-298. 10.1016/0006-3002(56)90010-5, 13363909.
4. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008, 60:59-68. 10.1016/j.addr.2007.06.011, 17826865.
5. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22:315-329. 10.2165/00063030-200822050-00004, 18778113.
6. Krystexxa (pegloticase) prescribing information 2012, Bridgewater, NJ: Savient Pharmaceuticals, Inc.
7. European Medicines Agency Krystexxa summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002208/WC500138318.pdf, European Medicines Agency.
8. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011, 306:711-720.
9. Baraf HSB, Matsumoto AK. Pegloticase: a new biologic for treating advanced gout. Int J Clin Rheumatol 2012, 7:143-154.
10. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007, 4:83-93. 1838823, 17396159.
11. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111. 10.1002/cncr.22739, 17516438.
12. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028. 10.1002/art.22403, 17328081.
13. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12. 10.1186/ar1861, 1526556, 16356199.
14. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007, 119:236-244. 10.1016/j.jconrel.2007.02.010, 17399838.
15. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008, 354:56-62. 10.1016/j.ijpharm.2007.11.005, 18083313.
16. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, Maeda T, Yamakawa N, Okamoto Y, Otsuka M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 2009, 26:2270-2279. 10.1007/s11095-009-9943-x, 19633820.
17. Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiology: The Immune System in Health and Disease 2001, New York: Garland Publishing, 5.
18. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984, 74:36-39. 10.1159/000233512, 6706424.
19. Liu Y, Reidler H, Pan J, Milunic D, Qin D, Chen D, Vallejo YR, Yin R. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods 2011, 64:238-245. 10.1016/j.vascn.2011.07.003, 21827863.
20. Belsey JD, Geraint M, Dixon TA. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010, 64:944-955. 10.1111/j.1742-1241.2010.02397.x, 20584228.
21. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010, 99:2557-2575. 10.1002/jps.22054, 2857543, 20049941.
22. Tang YC, Thoman M, Linton PJ, Deisseroth A. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged. Cancer Immunol Immunother 2009, 58:1949-1957. 10.1007/s00262-009-0718-3, 19444444.